Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entero Therapeutics, Inc. (ENTO : NSDQ)

• Company Description    Entero Therapeutics Inc. is a late clinical-stage biopharmaceutical company. It focused on the development of targeted, non-systemic therapies for gastrointestinal diseases. Entero Therapeutics Inc., formerly known as First Wave BioPharma Inc., is based in BOCA RATON, Fla. Number of Employees: 2

• Price / Volume Information    Yesterday's Closing Price: $3.15 Daily Weekly Monthly 20 Day Moving Average: 131,356 shares Shares Outstanding: 1.59 (millions) Market Capitalization: $5.00 (millions) Beta: 0.89 52 Week High: $3.29 52 Week Low: $0.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 71.19% 68.18% 12 Week 116.79% 96.92% Year To Date 68.79% 10.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 79014th St N Suite 21135 - St. Petersburg,FL 33431 USA ph: 561-589-7020 fax: - investors@firstwavebio.com http://www.firstwavebio.com

• General Corporate Information    Officers Richard Paolone - Chief Executive Officer Anna Skowron - Chief Financial Officer Edward J. Borkowski - Director Eric G. Corbett - Director Manpreet Uppal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 33749P507 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 1.59 Most Recent Split Date: 8.00 (0.33:1) Beta: 0.89 Market Capitalization: $5.00 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 95.85% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -1,063.82 12/31/24 - -212.26 ROA 06/30/25 - -17.94 03/31/25 - -26.06 12/31/24 - -18.14 Current Ratio 06/30/25 - 2.81 03/31/25 - 2.90 12/31/24 - 3.03 Quick Ratio 06/30/25 - 2.81 03/31/25 - 2.90 12/31/24 - 3.03 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - -3.96 03/31/25 - -3.29 12/31/24 - -2.45 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©